Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
SciScore for 10.1101/2020.09.11.20192518: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Ethics statement: This study was performed according to the Declaration of Helsinki and approved by the Medical Ethical Committee of the CHU de Lille.
Consent: Written informed consent forms were obtained from all enrolled living donors.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Analysis of anti-SARS-CoV-2 antibodies: Archived blood specimens collected on the day of donation for donor screening of infectious diseases were retrospectively tested for SARS-CoV-2 antibodies (Fig.2). SARS-CoV-2suggested: NoneThe SARS-CoV-2 chemiluminescent … SciScore for 10.1101/2020.09.11.20192518: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Ethics statement: This study was performed according to the Declaration of Helsinki and approved by the Medical Ethical Committee of the CHU de Lille.
Consent: Written informed consent forms were obtained from all enrolled living donors.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Analysis of anti-SARS-CoV-2 antibodies: Archived blood specimens collected on the day of donation for donor screening of infectious diseases were retrospectively tested for SARS-CoV-2 antibodies (Fig.2). SARS-CoV-2suggested: NoneThe SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) (Batch #17298FN00, controls batch #17100FN00 and #17531FN00, Abbott, Illinois, USA) is designed to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid (N) protein of SARS-CoV-2. immunoglobulin class G (IgGsuggested: NoneThe Wantai SARS-CoV-2 Ab is an enzyme-linked immunosorbent assays (ELISA) in a 96-well-plate format detecting total antibodies (including IgM and IgG) binding SARS-CoV-2 spike protein receptor binding domain (RBD). SARS-CoV-2 spike protein receptor binding domain ( RBD) .suggested: NoneSoftware and Algorithms Sentences Resources The SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) (Batch #17298FN00, controls batch #17100FN00 and #17531FN00, Abbott, Illinois, USA) is designed to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid (N) protein of SARS-CoV-2. Abbottsuggested: (Abbott, RRID:SCR_010477)External positive controls and donor samples were analyzed on an Abbott Architect i2000SR according to the manufacturer’s instructions. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
